GLP1R and type 2 diabetes mellitus: More importantly, owing to its incretin action, GLP-1 receptor agonists (GLP-1 RAs) developed from a DPP-4 resistant GLP-1 analog (exenatide or exendin-4 identified from the saliva of a venomous lizard) are currently utilized in type-2 diabetes therapy [5].